Latest news

• BMS' Empliciti approved by FDA for multiple myeloma

  BMS' Empliciti approved by FDA for multiple myeloma. Clearedfor use in with Celgene's Revlimid and corticosteroid dexamethasone. ... The new therapies provide new options for patients with multiple myeloma, the second most common form of blood cancer.

• Pfizer and Merck flesh out Xalkori alliance details

  BMS' Opdivo is used to treat melanoma and non-small cell lung cancer (NSCLC), with Merck's Keytruda (pembrolizumab) currently approved for melanoma only. ... Both drugs have multiple new indications coming through the pipeline, while additional

• AB Science on track for phase III data in Alzheimer's this year

  The drug is in trials for a host of cancer indications, including phase III studies in gastrointestinal stromal tumours (GIST), colorectal cancer, multiple myeloma and melanoma, as well as phase II ... Outside the cancer area it is being trialled in

• GSK and Bayer strike new biotech cancer deals

  It seems GSK still has interests in cancer, however, and will be looking to make the most of Adaptimmune's technology in cancer immunotherapies, which has shown promise in treating multiple ... myeloma, melanoma, sarcoma and ovarian cancer.

• Prix Galien shortlist announced

  Myers Squibb's melanoma treatment Yervoy (ipilimumab); Novartis' oral multiple sclerosis treatment Gilenya (fingolimod); Roche's Zelboraf (vemurafenib) for melanoma; Shire's Resolor (prucalopride) for chronic constipation in women; and